Objectives: This study aimed to evaluate the effectiveness and safety of medication abortion with misoprostol-only among patients treated by an abortion provider organization in the United States during the COVID-19 pandemic.
Study Design: We abstracted data from patients receiving misoprostol-only for abortion from December 2020 to December 2021. Two regimens were used, both allowing three to four doses of misoprostol 800 mcg every 3 hours but differing in the recommended administration routes (vaginal, buccal, or sublingual). We estimated the proportions of patients who had complete abortion and ongoing pregnancy in the two regimen groups in complete case analyses and after imputing missing outcomes based on pretreatment characteristics. We also estimated maximum effectiveness, assuming that all patients without known treatment failures had complete abortions. We tabulated serious adverse events.
Results: We ascertained abortion outcomes for 476 (52%) of the total 911 treated patients. Of the 476 patients, 389 (82%) had complete abortion confirmed by test or history, and 45 (9%) had ongoing pregnancies detected after the provision of treatment. These proportions did not differ significantly between the two regimen groups in adjusted complete case analyses (p > 0.44). The results of imputed analyses were similar. Of the total 911 patients, at most 90% (95% confidence interval 88%, 92%) had complete abortion, and at least 5% (95% confidence interval 4%, 7%) had ongoing pregnancy. Serious adverse events were reported in three patients (0.6% of 487 patients with data for this outcome).
Conclusions: Our analysis suggests that the misoprostol-only regimens studied were safe and effective for most patients. Due to high loss to follow-up, observations from patients contacted after treatment likely somewhat underestimate true effectiveness.
Implications: Medication abortion with misoprostol-only was safe and produced complete abortion in most patients with follow-up. If loss to follow-up is high, effectiveness observed by clinics may misestimate true treatment efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2023.110109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interest in digital health tools for miscarriage support: A qualitative assessment of Canadian women facing early pregnancy loss.
Womens Health (Lond)
January 2025
Vitala Global Foundation, Vancouver, BC, Canada.
Background: Early pregnancy loss (EPL) occurs in 10%-15% of all pregnancies but remains an underrecognized and undertreated condition. In Canada, resources to support individuals and their partners facing EPL remain scarce despite a high burden of psychosocial sequelae. Digital health tools hold the potential to fill important gaps in reproductive healthcare.
View Article and Find Full Text PDFEvaluation of the Pediatric Regional Anesthesia Time-Out Checklist: A Simulation Study.
Paediatr Anaesth
January 2025
University of Washington School of Medicine, Seattle, Washington, USA.
Introduction: The Society for Pediatric Anesthesia Quality and Safety Committee developed the Pediatric Regional Anesthesia Time-Out Checklist, consisting of 14 safety items intended to be reviewed by an anesthesia team prior to a regional anesthetic. Primarily, we hypothesized that use of this Checklist would increase the number of safety items performed compared with no checklist, evaluating the usefulness of this tool. Secondarily, we hypothesized that, after checklist training, subjects would show better clinical judgment by electing to perform a regional anesthetic in scenarios in which no programmed error existed and electing to not perform a regional anesthetic in scenarios in which a programmed error did exist.
View Article and Find Full Text PDFAbortion and contraception within prison health care: a qualitative study.
BMC Womens Health
January 2025
University of British Columbia Faculty of Medicine, Vancouver, BC, Canada.
Background: Although abortion was completely decriminalized in Canada 36 years ago, barriers to pregnancy prevention and termination persist across the country, such as travel and information gaps. Research demonstrates incarcerated people face barriers to family planning care, yet there is no systematic data collection of sexual and reproductive health experiences and outcomes among incarcerated people in Canada. The aim of this study was to explore family planning care experiences among women and gender diverse people who have experienced incarceration in Canada.
View Article and Find Full Text PDFA Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion.
NEJM Evid
January 2025
Gynuity Health Projects, New York.
Background: The current regimen for early medication abortion in many countries is mifepristone and misoprostol, but mifepristone is relatively expensive and limited in many regions. Ulipristal acetate, with a similar chemical profile, might be an alternative. This proof-of-concept study evaluated ulipristal acetate and misoprostol for medication abortion through 63 days of gestation.
View Article and Find Full Text PDFHyperkalaemia during a general anaesthetic in a 5-year-old domestic short-haired cat.
Aust Vet J
January 2025
Western Australian Veterinary Emergency and Specialty, Success, Western Australia, Australia.
This case report details an incident of hyperkalaemia that developed under general anaesthesia in a domestic cat with no prior health concerns. A 5-year-old male neutered domestic short-haired cat presented for dental extractions and subsequently developed severe bradycardia and electrocardiographic abnormalities during the procedure. Initial treatment with atropine provided limited improvement, and further investigation revealed a serum potassium concentration of 7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!